Category: Regulatory DisclosuresBy adminJune 16, 2023 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Disclosure regarding Rameda acquiring a selection of pharmaceutical products belong to diabetes and cholesterol treatment drugsNextNext post:Disclosure regarding the invitation to shareholders for the EGMRelated PostsRameda Announces New Chairman and Additions to its Board of DirectorsJune 3, 2026Rameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025BOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024
